Exogenous hormone use and fibrocystic breast disease by histopathologic component
Berkowitz G, Kelsey J, Livolsi V, Merino M, Holford T, Hildreth N, Ort S, O'Connor T, White C. Exogenous hormone use and fibrocystic breast disease by histopathologic component. International Journal Of Cancer 1984, 34: 443-449. PMID: 6490201, DOI: 10.1002/ijc.2910340403.Peer-Reviewed Original ResearchConceptsFibrocystic breast diseaseEstrogen replacement therapyBreast diseaseGross cystsReplacement therapyHospital-based case-control studyExogenous hormone useOral contraceptive usePost-menopausal womenCase-control studyPostmenopausal womenPremenopausal womenHormone useOral contraceptivesEpithelial atypiaControl womenPapillary hyperplasiaBiopsy specimensFibrocystic lesionsSurgical conditionsContraceptive useHistopathologic componentsWomenIncreased occurrenceDiseaseORAL CONTRACEPTIVE USE AND FIBROCYSTIC BREAST DISEASE AMONG PRE- AND POSTMENOPAUSAL WOMEN1
BERKOWITZ G, KELSEY J, LIVOLSI V, HOLFORD T, MERINO M, ORT S, O'CONNOR T, GOLDENBERG I, WHITE C. ORAL CONTRACEPTIVE USE AND FIBROCYSTIC BREAST DISEASE AMONG PRE- AND POSTMENOPAUSAL WOMEN1. American Journal Of Epidemiology 1984, 120: 87-96. PMID: 6741927, DOI: 10.1093/oxfordjournals.aje.a113878.Peer-Reviewed Original ResearchConceptsFibrocystic breast diseaseOral contraceptive useBreast diseaseOral contraceptivesContraceptive useHospital-based case-control studyOral contraceptive exposureGeneral surgical serviceCase-control studyLong-term useContraceptive exposurePostmenopausal women1Postmenopausal womenPremenopausal womenCystic diseaseStudy groupSurgical servicesDecreased frequencyPast usersDiseaseIncreased occurrenceWomenContraceptivesNegative associationAssociation